Skip to content
Back to LENZ

LENZ Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
8
Purchases
3
Sales
5
Purchase value
$365.58K
Sale value
$9.40M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Kolchinsky Peter10% owner
RA Capital Healthcare Fund LP10% owner
RA Capital Management, L.P.10% owner
Shah Rajeev M.10% owner
4
Filed Nov 2, 2026Period of report Oct 29, 20260001231919-26-001526
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 29, 2026
Common StockF1F2F32,159,516$3.36$7.26M1,159,823IndirectSee Footnotes
SaleOct 29, 2026
Common StockF1F2F4451,998$3.36$1.52M242,757IndirectSee Footnotes
SaleOct 29, 2026
Common StockF1F2F5107,170$3.36$360.09K57,559IndirectSee footnotes
Filing footnotes · 5
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.16 to $3.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  3. F3Held directly by the Fund.
  4. F4Held directly by the Nexus Fund II.
  5. F5Held directly by the Account.
Open on SEC EDGAR
Jeffrey P. GeorgeDirector
4
Filed Mar 30, 2026Period of report Mar 27, 20260001796789-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 27, 2026
Common StockF15,592$8.9217$49.89K5,592Direct
Filing footnotes · 1
  1. F1Represents the weighted average share price of an aggregate total of 5,592 shares purchased in the price range of $8.80 to $9.12 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Open on SEC EDGAR
Evert B. SchimmelpenninkDirector · President, CEO and Secretary
4
Filed Mar 30, 2026Period of report Mar 27, 20260001713795-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 27, 2026
Common StockF128,089$8.9505$251.41K77,289Direct
Filing footnotes · 1
  1. F1Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Open on SEC EDGAR
Daniel R. ChevallardChief Financial Officer
4
Filed Mar 30, 2026Period of report Mar 27, 20260001706176-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 27, 2026
Common Stock7,500$8.57$64.28K12,886Direct
Open on SEC EDGAR
Shawn OlssonChief Commercial Officer
4Rule 10b5-1 plan disclosed
Filed Nov 19, 2025Period of report Nov 17, 20250002015796-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 17, 2025
Common StockF1F24,212$25.7385$108.41K10,521Direct
SaleNov 17, 2025
Common StockF1F35,788$26.3669$152.61K4,733Direct
Filing footnotes · 4
  1. F1The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025.
  2. F2Represents the weighted average share price of an aggregate total of 4,212 shares sold in the price range of $25.12 to $26.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. F3Represents the weighted average share price of an aggregate total of 5,788 shares sold in the price range of $26.12 to $26.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. F4Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.